Updated: Nov 12
Medically reviewed by Dr Eric Wang- ChinaCureLink Team
When one doctor says bile duct cancer is too close to major blood vessels to remove, a family may wonder whether another surgical team would see the same scans differently. When the cancer has already spread, the more pressing question may be whether a tumor test could open up a new treatment option.
The best cholangiocarcinoma hospital for a patient in China is the one with experience in their exact bile duct cancer subtype and the treatment they need next. Three public centers to consider are Peking Union Medical College Hospital, West China Hospital, and Chinese PLA General Hospital. Ask the team to address the next decision, whether that is surgery, a matched drug, or a trial.
Key Takeaways |
• Match the hospital to the tumor location and the next treatment decision. • Chinese randomized evidence supports discussing preoperative therapy for selected high-risk intrahepatic tumors. • Fanregratinib has conditional approval in China for a defined FGFR2-positive group after prior treatment. • Confirm access, costs, and follow-up before travel. |
Table of Contents
The Hospital Team That Fits the Diagnosis
Cholangiocarcinoma can begin inside the liver (intrahepatic), where the main bile ducts meet (perihilar), or near the pancreas (distal). These locations call for different operations and surgical expertise.
For a surgical second opinion, look for a team that reviews the original scans together and routinely treats the same subtype. Ask who performs the operation and manages bile duct drainage and complications. If the cancer cannot be removed or has spread, prioritize a biliary cancer oncologist, molecular testing, and a clear plan for drug treatment. The wider guide to cancer treatment in China explains how to compare care pathways.
What China’s Research Adds to the Options
Treatment Before Surgery for High-Risk Intrahepatic Cancer
A 2026 randomized phase 2–3 trial led by Zhongshan Hospital, Fudan University, enrolled 178 people with high-risk intrahepatic tumors that could be removed. One group received gemcitabine and oxaliplatin, toripalimab, and lenvatinib before surgery. The other went straight to surgery. Both groups were assigned capecitabine afterward.
At the interim analysis, median event-free survival was 18.0 versus 8.7 months. This measures time until a defined event such as cancer recurrence or death. Overall survival fell short of the trial’s preset threshold for statistical significance, and 26% had grade 3 or higher treatment-related side effects during preoperative therapy. Ask a surgeon whether this approach fits the diagnosis and whether the hospital offers it.
An FGFR2-Targeted Option After Prior Treatment
China conditionally approved fanregratinib in August 2026 for adults with previously treated advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. In the 87-patient phase 2 registration cohort, the sponsor reported measurable tumor shrinkage in 42.5% and median progression-free survival of 6.9 months. Grade 3 or higher drug-related side effects occurred in 48.3%, including elevated liver enzymes and hand-foot reactions.
The study had no comparison group, so it could not establish a survival benefit over another drug. When exploring targeted therapy in China, send the complete molecular report and ask the hospital to confirm that it can prescribe and supply the drug for the individual case.
Public and Private Hospital Options for Cholangiocarcinoma
The shortlist draws on a national hepatobiliary surgery list informed in part by Fudan University’s Hospital Rankings. The card numbers show the order on that specialty list. General specialty rankings offer a starting point. They cannot establish bile duct cancer outcomes or tell families which team is right for an individual case. Families comparing Beijing hospitals for international patients can check each hospital’s international intake process separately.
Peking Union Medical College Hospital — Beijing
Its liver surgery department has a biliary malignancy group, and its international clinic lists liver surgery appointments.
West China Hospital, Sichuan University — Chengdu
Its dedicated biliary surgery department reports complex resections for perihilar cholangiocarcinoma.
Chinese PLA General Hospital — Beijing
Its First Medical Center has a hepatobiliary and pancreatic surgery department. Confirm the campus and international intake route before planning a visit.
Where Private Cancer Hospitals May Fit
In Guangzhou, Fuda Cancer Hospital lists cryoablation and other local procedures. Modern Cancer Hospital Guangzhou lists image-guided interventional treatments. Guangzhou Concord Cancer Center lists medical oncology, radiotherapy, and remote second-opinion intake. RoyalLee Cancer Hospital lists dedicated radiotherapy services. These services may be relevant when a bile duct cancer team identifies a specific role for radiation or a local procedure. For a potentially removable tumor, seek a surgical review first. Comparable disease-specific outcomes were unavailable across these private centers and the public referral teams above.
Treatment Access, Costs, and Care After Travel
Gemcitabine and cisplatin plus an immunotherapy drug such as durvalumab is an established first-line option for eligible patients with advanced biliary tract cancer. In the 685-patient phase 3 TOPAZ-1 trial, median overall survival was 12.9 versus 11.3 months with chemotherapy alone. Grade 3 or 4 adverse events occurred in 74% and 75%, respectively. The trial included several biliary cancer types.
Patients with an FGFR2 alteration may also have options closer to home. The EU authorized pemigatinib for eligible patients after prior treatment, and the US FDA approved lirafugratinib in September 2026 for a defined previously treated FGFR2-positive group. Different trial populations and follow-up make response rates unsuitable for ranking the drugs.
Records, access, and follow-up can change travel plans. Send original scans, pathology and the full molecular report. When reviewing cancer clinical trials in China, confirm that the specific site is recruiting and can screen overseas patients.
Before comparing cancer treatment costs in China, request an itemized estimate that covers tests, drugs or surgery, the hospital stay, and possible stent care. Ask what is excluded, how long to stay, and who will manage follow-up after returning home.
What to Expect When Booking Directly
A family can send records to a hospital’s international patient office and ask for a written specialist opinion, itemized estimate, and proposed schedule. Ask each center the same question so the answers are easier to compare.
Independent Guidance Before Travel
ChinaCureLink, a Medebound HEALTH company, represents patients. Its team can review records and identify up to three relevant hospitals or specialists. Hospital and specialist matching is free. Video second opinions are paid consultations, with fees confirmed before booking. The initial advisory call is free. Read how hospital matching works.
A Published CAR-T Case From China
In a 2017 report from Chinese PLA General Hospital, a 52-year-old woman with metastatic cholangiocarcinoma had an 8.5-month partial response after EGFR-directed CAR-T. After the disease progressed, CD133-directed CAR-T produced another partial response lasting 4.5 months. The report describes serious skin and fluid-related side effects during the second treatment. These intervals describe tumor response. The report does not establish an overall survival benefit.
Individual results vary. For cholangiocarcinoma, CAR-T for solid tumors remains investigational. Ask a biliary cancer specialist for a second opinion before traveling for an experimental treatment.
What Patients Say About ChinaCureLink & Medebound HEALTH
The following feedback describes patients’ experiences with the coordination service.

Practical Next Steps
Put one decision at the top of the referral. Can the tumor be removed, or does the molecular report point to another treatment? Confirm the diagnosis, compare qualified teams, and review eligibility, costs, risks, and follow-up before making plans to travel to China for medical treatment.
Frequently Asked Questions
Is There One Best Bile Duct Cancer Hospital in China?
The strongest match depends on tumor location and the next treatment decision. For a perihilar tumor, ask about experience operating where the ducts meet. For disease that has spread, ask about biliary oncology and access to molecular testing.
Can an International Patient Get Fanregratinib in China?
Potentially, if the patient fits the approved indication and the receiving hospital can prescribe and supply it. Send the FGFR2 report and treatment history, then confirm monitoring and refills.
What Does a Second-Opinion Team Need to Review?
Send the pathology report, original CT or MRI files, recent blood tests, and a timeline of surgery, stents, and drug treatments. For advanced disease, include the full molecular testing report if available.
How Much Does Cholangiocarcinoma Treatment Cost in China?
Costs depend on the proposed plan. Request a written quote separating hospital and clinician fees, tests, drugs, and follow-up. Ask how extra inpatient days and unplanned procedures are billed.
Bottom Line
China is worth considering when a specialist team can answer a specific question about complex bile duct surgery, treatment before surgery, or a confirmed tumor marker. A remote specialist opinion can help a family weigh that option against care closer to home before making travel plans.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
You may also like:
Read about a cholangiocarcinoma second opinion for a patient from Malaysia.
Learn how to book an oncology appointment in China before traveling.